Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule inhibitors of Poly-Adenyl-Ribose Polymerase (PARP) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi’s PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors.
The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi’s PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors.
The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- Small Molecule Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
- Corporate PARP Inhibitors R&D Pipelines
